May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more
Chiesi gains rights to Santhera's Raxone for LHON
Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic neuropathy and all other ophthalmological indications; the short-chain benzoquinone received EU approval for LHON in 2015. Santhera will receive CHF50 million ($49.5 million) up front and is eligible for sales milestones of up to CHF55 million ($54.4 million). Chiesi has an option to acquire full rights.
WuXi enters long-term vaccine manufacturing deal
WuXi Biologics Inc. (HKSE:2269) said its WuXi Vaccines JV will build an integrated vaccine manufacturing facility to supply an undisclosed company with commercial vaccine product under a 20-year deal worth more than $3 billion. WuXi Vaccines is a JV between WuXi Biologics and Shanghai Hile Bio-Technology Co. Ltd. (Shanghai:603718)...